证券代码：688098 证券简称：申联生物 公告编号：2025-024 申联生物医药(上海)股份有限公司 关于获批兽药产品批准文号的自愿性披露公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》《兽药产品批准文号管理办法》等有关规定，经中华 人民共和国农业农村部审查，准予申联生物医药（上海）股份有限公司兰州分 公司生产猪瘟基因工程亚单位疫苗（CHO-133D），并核发兽药产品批准文号批 件，具体情况如下： 一、兽药产品批准文号基本情况 1、通用名称：猪瘟基因工程亚单位疫苗（CHO-133D） 4、有效期：2025年6月24日至2030年6月23日 二、兽药产品及其市场情况 猪瘟基因工程亚单位疫苗（CHO-133D）用于预防猪瘟。猪瘟（Infection with classical swine fever virus，简称 CSF）是由猪瘟病毒（CSFV）引起的一种高度急 性、热性、接触性传染病。该病以发病急、发生高热稽留和细小血管壁变性、全 身泛发性小点出血、脾梗死为特征。该病一年四季流行，可对养猪业造成 ...

Core Viewpoint - The company Shunlian Bio has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its genetically engineered subunit vaccine for swine fever, along with the issuance of the veterinary drug product approval number [1] Group 1 - The approval signifies a significant milestone for the company's product development in the veterinary vaccine sector [1] - The vaccine is expected to enhance the company's market position in the animal health industry [1] - This development may lead to increased revenue opportunities for the company in the future [1]

关于股份回购实施结果暨股份变动的公告 证券代码：688098 证券简称：申联生物 公告编号：2025-023 申联生物医药（上海）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/11/26 | | --- | --- | | 回购方案实施期限 | 2024年11月26日~2025年5月25日 | | 预计回购金额 | 2,000万元~4,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 3,417,373股 | | 累计已回购股数占总股本比例 | 0.8322% | | 累计已回购金额 | 20,000,452.13元 | | 实际回购价格区间 | 5.47元/股~6.29元/股 | （一）2024年12月5日，公司首次实施回购股份。具体内容详见公司于2024年 12月6日在上海证券交易所网站（www.sse.com.cn）上披露的《关于以集中竞 ...

Core Viewpoint - The company has approved a share repurchase plan aimed at enhancing employee stock ownership and incentivizing through equity incentives or convertible bond conversions [1] Summary by Relevant Sections Share Repurchase Plan - The company plans to repurchase shares with a budget of 20 million to 40 million yuan through centralized bidding [1] - The board approved this plan on November 25, 2024 [1] Repurchase Details - As of May 23, 2025, the company has repurchased a total of 3.4174 million shares, which represents 0.8322% of the total share capital [1] - The repurchase price range was between 5.47 yuan and 6.29 yuan per share [1] - The total funds used for the repurchase amounted to 20.0005 million yuan, excluding transaction fees [1] Future Use of Repurchased Shares - The repurchased shares will be held in a dedicated securities account for future plans and must be utilized or legally processed within the stipulated timeframe [1]

国浩律师（上海）事务所 法律意见书 本所律师同意将本法律意见书作为公司本次股东大会的必备文件公告，并依 法对本所出具的法律意见承担责任。 本所律师已经对与出具法律意见书有关的所有文件材料及证言进行审查判 断，并据此出具法律意见如下： 一、本次股东大会的召集、召开程序 国浩律师（上海）事务所 关于申联生物医药（上海）股份有限公司 2024 年年度股东大会的法律意见书 致：申联生物医药（上海）股份有限公司 申联生物医药（上海）股份有限公司（以下简称"公司"）2024 年年度股东大 会（以下简称"本次股东大会"）现场会议定于 2025 年 5 月 20 日下午 14:30 在上 海市闵行区江川东路 48 号公司综合楼一楼会议室召开，国浩律师（上海）事务 所（以下简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华 人民共和国证券法》、《中华人民共和国公司法》、《申联生物医药（上海）股 份有限公司章程》（以下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-022 申联生物医药（上海）股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 20 日 （二） 股东大会召开的地点：上海市闵行区江川东路 48 号公司综合楼一楼 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 55 | | --- | --- | | 普通股股东人数 | 55 | | 2、出席会议的股东所持有的表决权数量 | 221,320,600 | | 普通股股东所持有表决权数量 | 221,320,600 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 54.3482 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.3482 | ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

证券代码：688098 证券简称：申联生物 公告编号：2025-021 申联生物医药（上海）股份有限公司 关于参加 2025 年上海辖区上市公司年报集体业绩说 明会暨举行 2025 年第一季度报告业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 本次投资者说明会以网络互动形式召开，公司将针对 2024 年年 度及 2025 年第一季度的经营成果及财务指标的具体情况与投资者进 行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问 题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 8 日 ...

Core Viewpoint - The financial performance of Shenyuan Biological in 2024 shows a decline in net profit and a slight increase in revenue, indicating potential challenges ahead for the company. Financial Performance Summary - In 2024, the company achieved operating revenue of 30,341.47 million yuan, a year-on-year increase of 0.64% compared to 30,148.71 million yuan in 2023 [1][2] - The net profit attributable to shareholders was -4,474.01 million yuan, a significant decrease from the previous year's profit of 3,151.87 million yuan, representing a decline of 241.95% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -4,837.65 million yuan, down from 2,506.98 million yuan in the prior year, marking a decrease of 292.97% [1][2] - The net cash flow from operating activities was 8,936.20 million yuan, a substantial increase from 352.55 million yuan in the previous year, reflecting a growth of 2,434.71% [1][2] Q1 2025 Performance Summary - In the first quarter of 2025, the company reported operating revenue of 7,874.11 million yuan, a year-on-year decrease of 10.58% from 8,805.82 million yuan [3][4] - The net profit attributable to shareholders was -301.99 million yuan, compared to -220.92 million yuan in the same period last year [3][4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -445.01 million yuan, down from -286.93 million yuan in the previous year [3][4] - The net cash flow from operating activities was -2,856.10 million yuan, compared to -2,440.44 million yuan in the same period last year [3][4] Company Background - Shenyuan Biological was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2019, with an initial issuance of 50 million shares at a price of 8.80 yuan per share [4][5] - The highest stock price recorded was 36.88 yuan on the first trading day, but the stock is currently in a state of decline [4]

证券代码：688098 证券简称：申联生物 公告编号：2025-020 重要内容提示： | 回购方案首次披露日 | 2024/11/26 | | --- | --- | | 回购方案实施期限 | 2024年11月26日~2025年5月25日 | | 预计回购金额 | 2,000万元~4,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | √用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 3,417,373股 | | 累计已回购股数占总股本比例 | 0.8322% | | 累计已回购金额 | 20,000,452.13元 | | 实际回购价格区间 | 5.47元/股~6.29元/股 | 一、回购股份的基本情况 公司于2024年11月25日召开第三届董事会第十五次会议，会议审议通过了 《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金 和自筹资金通过上海证券交易所系统以集中竞价交易方式回购公司已发行的部 分人民币普通股（A股）股票。本次回购的股份将在未来适宜时机用于员工持股 计划或者股权激励，或用于转换上市公司发行的可转换为股票 ...